Real-World check: Takhzyro's safety tracked in korean HAE patients
NCT ID NCT07445087
First seen Mar 30, 2026 · Last updated May 25, 2026 · Updated 10 times
Summary
This study monitors the safety and effectiveness of Takhzyro, an approved drug for hereditary angioedema (HAE), in teenagers and adults in South Korea. HAE causes sudden swelling under the skin or inside the body. About 35 participants will be followed during their regular medical care to track side effects and how well the drug controls swelling attacks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.